FDA Diabetes Drug Inquiry Finds No Cancer Risks

Law360, New York (July 31, 2013, 5:57 PM ET) -- The U.S. Food and Drug Administration said Wednesday it has found no evidence that a class of diabetes drugs made by Merck & Co. Inc., Bristol-Myers Squibb Co. and others is linked to pancreatic cancer, after European regulators closed a parallel probe last week.

The FDA said it concurs with the European Medicines Agency, which determined on Friday that available data does not confirm recent concerns that a class of type 2 diabetes drugs called incretin mimetics carry an increased risk of pancreatic cancer. The FDA's own...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required